Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

Blood (2014) 123 (15): 2333–2342.

https://doi.org/10.1182/blood-2013-12-542720

Published: 2014

Includes: Supplemental data

Journal Articles

High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect

Anna Dodero, MD, Francesco Spina, MD PhD, Barbara Sarina, MD, Cristiana Carniti, Francesca Patriarca, MD, Angelo Michele Carella, Alessandro Levis, Alberto Bosi, MD, Michele Falda, MD, Paolo Di Bartolomeo, MD, Francesco Onida, MD, Serena Dalto, MD, Antonio Vendramin, Alessandro Rambaldi, MD, Paolo Corradini

Blood (2013) 122 (21): 2059.

https://doi.org/10.1182/blood.V122.21.2059.2059

Published: 2013

Journal Articles

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

Peter Dreger, MD, Herve Finel, Renato Fanin, MD, Paolo Corradini, MD, Michele Falda, MD, Jürgen Finke, MD, William Arcese, MD, Piero Galieni, MD, Luca Castagna, MD, Domenico Russo, Mats L Brune, Rosanna Scimè, MD, Enrico Maria Pogliani, MD, Fabio Benedetti, MD, Norbert Schmitz, MD, Ariane Boumendil

Blood (2012) 120 (21): 2033.

https://doi.org/10.1182/blood.V120.21.2033.2033

Published: 2012

Journal Articles

In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Blood (2012) 120 (21): 221.

https://doi.org/10.1182/blood.V120.21.221.221

Published: 2012

Journal Articles

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Blood (2012) 119 (6): 1599–1606.

https://doi.org/10.1182/blood-2011-08-375840

Published: 2012

Includes: Supplemental data

Journal Articles

Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

Blood (2011) 118 (21): 2009.

https://doi.org/10.1182/blood.V118.21.2009.2009

Published: 2011

Journal Articles

Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS)

Blood (2011) 118 (21): 116.

https://doi.org/10.1182/blood.V118.21.116.116

Published: 2011

Journal Articles

High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas

Paolo Corradini, Barbara Sarina, MD, Cristiana Carniti, PhD, Francesca Patriarca, MD, Angelo Michele Carella, MD, Alessandro Levis, Alberto Bosi, MD, Michele Falda, Paolo Di Bartolomeo, MD, Cecilia Olivares, MD, Silvia Gimondi, Antonio Vendramin, Anna Dodero, MD

Blood (2011) 118 (21): 4546.

https://doi.org/10.1182/blood.V118.21.4546.4546

Published: 2011

Journal Articles

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Blood (2010) 115 (18): 3671–3677.

https://doi.org/10.1182/blood-2009-12-253856

Published: 2010

Journal Articles

Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Alessandro Busca, MD, Michele Falda, Paola Manzini, Sergio D’antico, Franco Locatelli, Annalisa Chiappella, Stefano D’Ardia, Filomena Longo, MD, Roberto Calabrese, Antonio Piga, MD

Blood (2008) 112 (11): 2134.

https://doi.org/10.1182/blood.V112.11.2134.2134

Published: 2008

Journal Articles

RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLATyping and Donor Availability

Barbara Sarina, MD, Luca Castagna, MD, Fabio Benedetti, MD, Francesca Patriarca, MD, Michele Malagola, MD, Silvia Ferrari, MD, Roberto Sorasio, MD, Lucia Farina, MD, Enrico Morello, MD, Alessandro Bonini, MD, Nicola Mordini, MD, Sergio Tamiazzo, MD, Michele Falda, MD, Laura Giordano, PhD, Paolo Corradini, MD

Blood (2008) 112 (11): 460.

https://doi.org/10.1182/blood.V112.11.460.460

Published: 2008

Journal Articles

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Emilio Paolo Alessandrino, Matteo Giovanni Della Porta, Andrea Bacigalupo, Maria Teresa Van Lint, Michele Falda, Francesco Onida, Massimo Bernardi, Anna Paola Iori, Alessandro Rambaldi, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Luca Malcovati, Cristiana Pascutto, Rosi Oneto, Renato Fanin, Alberto Bosi

Blood (2008) 112 (3): 895–902.

https://doi.org/10.1182/blood-2008-03-143735

Published: 2008

Journal Articles

Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.

Roberto Crocchiolo, MD, Fabio Ciceri, MD, Rosa Oneto, MD, Barbara Bruno, MD, Simona Pollichieni, MD, Nicoletta Sacchi, MD, Maria Pia Sormani, MD, Renato Fanin, MD, Giuseppe Bandini, MD, Alberto Bosi, MD, Alessandro Rambaldi, MD, Paolo Emilio Alessandrino, MD, Michele Falda, MD, Andrea Bacigalupo, MD

Blood (2007) 110 (11): 3052.

https://doi.org/10.1182/blood.V110.11.3052.3052

Published: 2007

Journal Articles

WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.

Paolo E. Alessandrino, MD, Matteo G. Della Porta, MD, Andrea Bacigalupo, MD, Maria Teresa Van Lint, MD, Michele Falda, MD, Francesco Onida, MD, Massimo Bernardi, MD, Anna P. Iori, MD, Alessandro Rambaldi, MD, Raffaella Cerretti, MD, Paola Marenco, MD, Pietro Pioltelli, MD, Cristiana Pascutto, PhD, Rosi Oneto, BS, Renato Fanin, MD, Alberto Bosi, MD

Blood (2007) 110 (11): 1466.

https://doi.org/10.1182/blood.V110.11.1466.1466

Published: 2007

Journal Articles

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Blood (2006) 108 (11): 3158.

https://doi.org/10.1182/blood.V108.11.3158.3158

Published: 2006

Journal Articles

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes

Blood (2006) 108 (3): 836–846.

https://doi.org/10.1182/blood-2005-11-4503

Published: 2006

Journal Articles

Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.

Alessandro Busca, MD, Franco Locatelli, MD, Stella Santarone, MD, Franco Narni, MD, Enrico Morello, MD, Alessandro Rambaldi, MD, Nicola Mordini, MD, Benedetto Bruno, MD, Andrea Bacigalupo, MD, Michele Falda, MD

Blood (2004) 104 (11): 5134.

https://doi.org/10.1182/blood.V104.11.5134.5134

Published: 2004

Journal Articles

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow

Norbert C. Gorin, Myriam Labopin, Vanderson Rocha, William Arcese, Meral Beksac, Eliane Gluckman, Olle Ringden, Tapani Ruutu, Josy Reiffers, Giuseppe Bandini, Michele Falda, Panagiotis Zikos, Roelf Willemze, Francesco Frassoni, for the Acute Leukemia Working Party (ALWP) of the European Cooperative Group for Blood and Marrow Transplantation (EBMT)

Blood (2003) 102 (8): 3043–3051.

https://doi.org/10.1182/blood-2003-03-0665

Published: 2003

Journal Articles

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

Paolo Corradini, Corrado Tarella, Attilio Olivieri, Alessandro M. Gianni, Claudia Voena, Francesco Zallio, Marco Ladetto, Michele Falda, Moira Lucesole, Anna Dodero, Fabio Ciceri, Fabio Benedetti, Alessandro Rambaldi, Maria R. Sajeva, Moreno Tresoldi, Alessandro Pileri, Claudio Bordignon, Marco Bregni

Blood (2002) 99 (1): 75–82.

https://doi.org/10.1182/blood.V99.1.75

Published: 2002

Journal Articles

Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All- trans Retinoic Acid and Idarubicin (AIDA) Therapy

Blood (1997) 90 (3): 1014–1021.

https://doi.org/10.1182/blood.V90.3.1014

Published: 1997

NARROW

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R

High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect

Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party

In Vivo T Cell Depletion with Antithymocyte Globulin or Alemtuzumab for Unrelated Donor Stem Cell Transplantation with Reduced Intensity Conditioning: Results of a Multicenter Randomized Phase II Clinical Trial (The Global Study) From the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry

Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Who Classification-Based Prognostic Scoring System (WPSS)

High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Quantification by Superconducting Quantum Interference Device (SQUID) of Iron Overload after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLATyping and Donor Availability

WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Effect of HLA-Matching on Outcome of Hematopoietic Stem Cell Transplantation from Unrelated Donors: A IBMDR-GITMO Study.

WHO Classification and WPSS Score Predict Post-Transplant Outcome in Adults with Myelodysplastic Syndrome: A Retrospective Study by GITMO - Gruppo Italiano Trapianto Midollo Osseo.

Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.

Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes

Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies

Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All- trans Retinoic Acid and Idarubicin (AIDA) Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only